Abstract:BACKGROUND:Chemotherapy is one of major therapeutic regimens for neuroblastoma (NB) in children. However, recurrence and metastasis associated with poor prognosis caused by acquired multidrug resistance remains a challenge. There is a great need to achieve new insight into the molecular mechanism of drug resistance in NB. The aim of this study is to identify novel drug sensitivity-related biomarkers as well as new therapeutic targets to overcome chemoresistance.METHODS:We proteome-wide quantitatively compared protein expression of two NB cell lines with different drug sensitivities, isolated from the same patient prior to and following chemotherapy. Annexin A2 (ANXA2) emerged as a key factor contributing to drug resistance in NB. Then, we assessed the correlation of ANXA2 expression and clinical characteristics using a tissue microarray. Further, the roles of ANXA2 in chemoresistance for NB and the underlying mechanisms were studied by using short hairpin RNA (shRNA) in vitro and vivo.RESULTS:First in total, over 6000 proteins were identified, and there were about 460 significantly regulated proteins which were up- or down-regulated by greater than two folds. We screened out ANXA2 which was upregulated by more than 12-fold in the chemoresistant NB cell line, and it might be involved in the drug resistance of NB. Then, using a tissue chip containing 42 clinical NB samples, we found that strong expression of ANXA2 was closely associated with advanced stage, greater number of chemotherapy cycles, tumor metastasis and poor prognosis. Following knockdown of ANXA2 in NB cell line SK-N-BE(2) using shRNA, we demonstrate enhanced drug sensitivity for doxorubicin (2.77-fold) and etoposide (7.87-fold) compared with control. Pro-apoptotic genes such as AIF and cleaved-PARP were upregulated. Inhibiting ANXA2 expression attenuated transcriptional activity of NF-κB via down-regulated nuclear translocation of subunit p50. Finally, simulated chemotherapy in a xenograft NB nude mouse model suggests that ANXA2 knockdown could improve clinical results in vivo.CONCLUSION:Our profiling data provided a rich source for further study of the molecular mechanisms of acquired drug resistance in NB. Further study may determine the role of ANXA2 as a prognostic biomarker and a potential therapeutic target for patients with multidrug-resistant NB.

Cracking the code of Annexin A1-mediated chemoresistance

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review)

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Annexin A1 in inflammation and breast cancer: a new axis in the tumor microenvironment

Annexin I and Tumor

Advances in cancer treatment: a new therapeutic target, Annexin A2

Association of annexin A2 with cancer development (Review).

Involvement of Annexin A1 in Multidrug Resistance of K562/ADR Cells Identified by the Proteomic Study

Annexin A protein family: Focusing on the occurrence, progression and treatment of cancer.

Targeting Annexin A1 as a Druggable Player to Enhance the Anti-Tumor Role of Honokiol in Colon Cancer through Autophagic Pathway

Annexin A2 Could Enhance Multidrug Resistance by Regulating NF-κB Signaling Pathway in Pediatric Neuroblastoma.

Annexin A2 is Implicated in Multi-Drug-resistance in Gastric Cancer Through P38mapk and AKT Pathway.

Decreased Annexin A1 Expression Enhances Sensitivity to Docetaxel, Cisplatin and 5-Fluorouracil Combination Induction Chemotherapy in Oral Squamous Cell Carcinoma

Increased Expression of Annexin I is Associated with Drug‐resistance in Nasopharyngeal Carcinoma and Other Solid Tumors

Annexin-I Expression Modulates Drug Resistance in Tumor Cells.

Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.

Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

Crucial Role of Anxa2 in Cancer Progression: Highlights on Its Novel Regulatory Mechanism

Annexin A1: Uncovering the Many Talents of an Old Protein

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer